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ABSTRACT 
PURPOSE: We report cardiac events in the Persephone trial which compares six to 
twelve months adjuvant trastuzumab in women with confirmed HER2 positive, early 
stage breast cancer. 
 
PATIENTS AND METHODS: Clinical cardiac events were defined as any of the 
following, symptoms and/or signs of congestive heart failure (CHF) and new or 
altered CHF medication.  In addition left ventricular ejection fraction (LVEF) was 
measured at baseline and then 3-monthly for 12 months. 
 
RESULTS: 2500 patients, aged 22-82, were included; 1251 randomised to 12-
months and 1249 to 6-months trastuzumab. 93% (2335/2500) received 
anthracyclines, 49% of these (1136/2335) with taxanes. Cardiotoxicity delayed 
treatment in 6% of 12-month and 4% of 6-month patients (p=0.01), and stopped 
treatment early in 8% (96/1214) of 12-month and 4% (45/1216) of 6-month patients 
(p<0.0001). Between 7 and 12 months, more 12-month than 6-month patients had 
LVEFs<50% (8% vs 5%; p=0.004). LVEFs showed quadratic change over time and 
6-month patients had a more rapid recovery (p=0.02). In a landmark analysis twice 
as many 12-month patients, free of cardiac events at 6 months, had cardiac 
problems in months 7 to 12 (6% [66/1046] vs 3% [29/1035] of 6-month patients 
(p=0.0002)). Lower baseline LVEF predicted more cardiac dysfunction in both arms 
(reference >65%: 55-<65% OR 1.61 [95%CI 1.26-2.04]; <55% OR 5.22 [3.42-7.95]) 
as did increasing age (reference <50: 50-59 OR 1.58 [1.17-2.12], 60-69 OR 1.91 
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[1.42-2.57]) 70+ OR 2.72 [1.82-4.08]). Two factors were associated with higher risk 
of cardiac events for 12-month compared with 6-month patients: >3 cycles of 
anthracycline (OR 1.43 [1.06-1.92] and 1.12 [0.81-1.55] respectively); and prior 
cardiac medication (OR 5.88 [2.55-13.54] and 12.47 [5.14-30.25]).  
 
CONCLUSION: We demonstrate significantly fewer cardiac events from 6 months 
adjuvant trastuzumab compared with 12 months. This cardiac signal adds 
importance to the question of the optimum duration of adjuvant trastuzumab 
treatment. If 6 months is proven to have non-inferior outcomes to 12 months 
treatment, these data would support 6 months as the standard of care. 
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INTRODUCTION 
Trastuzumab has transformed the treatment of HER2 positive breast cancer both in 
the adjuvant and the metastatic settings. The results of the US and international 
adjuvant trastuzumab trials published in 2005-7 (Piccart-Gebhart et al, 2005; 
Romond et al, 2005; Hortobagyi, 2005; Slamon et al, 2011), resulted in a paradigm 
shift in treatment and established 12 months of adjuvant trastuzumab as the 
standard of care. Previously HER2 positive breast cancer was associated with poor 
outcomes. The METABRIC genomic analysis of nearly 2000 breast cancer patients, 
serves as a reminder of the poor prognosis particularly for high risk ER negative 
HER2 positive patients prior to the introduction of adjuvant trastuzumab (Curtis et al, 
2012; Dawson et al, 2013). The HERA trial has reported long term follow-up results 
(Goldhirsch A et al, 2013) which have demonstrated a robust improvement in 
disease-free and overall survival with 12 months of adjuvant trastuzumab but no 
incremental clinical benefit from extending adjuvant treatment to 24 months.  
 
Cardiac dysfunction with reduced left ventricular ejection fraction has been 
recognized as a side effect of trastuzumab therapy since the early days of its use 
(Seidman et al, 2002)8 and has since been reported in all adjuvant trials (Tan-Chiu et 
al, 2005; Suter et al, 2007; Procter et al, 2010; de Azambuja et al, 2014; Perez et al, 
2008; Russell et al, 2010). The pathophysiology of the observed cardiac toxicity is 
not completely understood. HER2 receptors are present on cardiac myocytes, and 
without normal HER2 function, there may be accumulation of reactive oxygen 
species resulting in dysfunction (Zeglinski et al, 2011). Trastuzumab may also impair 
mitochondrial function through intracellular downstream events resulting in ATP 
depletion and therefore contractile dysfunction (Force, Krause, van Etten, 2007). 
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Sequential cardiac stresses from anthracycline administration preceding 
trastuzumab treatment are also likely to significantly contribute to cardiac problems 
(Ewer et al, 1999; Ewer et al, 2005). The PHARE trial, which has also looked at 
reducing trastuzumab duration to 6 months compared with the standard of 12 
months (Pivot et al, 2013), demonstrated a reduction in cardiac dysfunction to 4% in 
the 6 month arm (Pivot et al, 2015). The cardiac data from the PHARE (Pivot et al, 
2015), HERA (Tan-Chiu et al, 2005; Suter et al, 2007; Procter et al, 2010; de 
Azambuja et al, 2014) trials and the US studies (Perez et al, 2008; Russell et al, 
2010) show a clear relationship between the duration of trastuzumab exposure and 
incidence of cardiac dysfunction. Notwithstanding this important finding, there are 
increasing numbers of patients on trastuzumab for long periods of time in the 
metastatic setting, and in these patients there seems little objective data to indicate a 
cumulative dose form of toxicity as seen with anthracyclines (Mantarro et al, 2016; 
Jensen, 2006). 
 
There would be clear advantages in reducing the risk of cardiac dysfunction, if the 
duration of adjuvant trastuzumab could be shortened to 6 months or less without 
sacrificing clinical efficacy. From 2007 to the end of July 2015, the Persephone trial 
randomized HER2 positive patients to either 6 or 12 months trastuzumab (Earl et al, 
2014). We present here the cardiology sub-study with the pre-specified secondary 
endpoint of cardiac function in the first 2500 patient cohort. The Persephone trial was 
designed to ‘map onto standard practice’ in the UK and therefore our results will be 
applicable to ‘real world patients’. 
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PATIENTS AND METHODS 
Study design 
The Persephone trial is a UK phase III randomized non-inferiority trial comparing 6 
months of trastuzumab to the standard 12 month duration in women with 
histologically confirmed HER2 positive early invasive breast cancer receiving a 
standard chemotherapy regimen in the adjuvant or neo-adjuvant setting. These 
patients had stage I-IIIa disease. This trial was approved by Multi-Research Ethics 
Committee (07/MRE08/35), is conducted in accordance with the declaration of 
Helsinki and supported by the NCRN (No 4078). 
  
The primary endpoint is disease-free survival (DFS), with cardiac function a 
secondary endpoint. The Data and Safety Monitoring Committee reviewed full 
cardiac data on the first 2500 patients and advised both a reduction in frequency of 
LVEF measurements from 3-monthly to the new UK standard practice (minimum 4-
monthly) (Jones et al, 2009) as well as the publication of the sub-study cardiac event 
data ahead of the primary endpoint of the trial. 
 
These 2500 patients were randomized to receive trastuzumab intravenously (IV) for 
either 12 months (18 cycles) or 6 months (9 cycles) using a schedule of one loading 
dose of 8mg per kilogram of body weight (/kg) IV followed by 3-weekly maintenance 
doses of 6mg/kg IV. Trastuzumab administration could be concurrently with taxane 
(but not anthracyclines) or sequentially. 
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Participants 
Inclusion criteria were: histological diagnosis of invasive breast cancer; no evidence 
of metastatic disease; known hormone receptor status; overexpression of HER2 
receptor; bilateral breast cancers provided one of the tumours overexpresses HER2 
receptor; clear indication for neo-adjuvant or adjuvant chemotherapy based on 
clinical and histopathological features; patient fit to receive neo-adjuvant or adjuvant 
chemotherapy and trastuzumab in the opinion of the responsible physician; no 
previous diagnosis of malignancy unless (i) managed by surgical treatment only and 
disease-free for 10 years or (ii) previous basal cell carcinoma, cervical carcinoma in 
situ or ductal carcinoma in situ of the breast; non-pregnant and non-lactating, with no 
intention of pregnancy during chemotherapy, and agrees to adopt adequate 
contraceptive measures if pre-menopausal and sexually active; no concomitant 
medical or psychiatric problems that might prevent completion of treatment or follow-
up; patients 18 years or older; and written informed consent for the study given at 
any time before the 10th cycle of trastuzumab. Exclusion criteria were: significant 
concomitant cardiac disease or other co-morbidity which in the opinion of the 
responsible physician added to the risks associated with trastuzumab or cytotoxic 
chemotherapy; inability to comply with protocol requirements; and patients having 
already received more than 9 cycles of trastuzumab prior to randomisation. 
In particular participants should have no significant cardiac disease or co-morbidity 
that added to the cardiac risks associated with trastuzumab and chemotherapy, in 
the opinion of the principal investigator (PI). However, Persephone was a trial 
designed to 'map onto standard practice' and therefore did not exclude any patients 
who, in the opinion of the PIs at recruiting sites, would otherwise be considered fit 
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enough to receive chemotherapy and the standard of 12 months adjuvant 
trastuzumab.  
Randomisation and masking 
The trial was open label and we randomly assigned patients (1:1) to 12-months or 6-
months trastuzumab using a central computerized minimization procedure. 
Stratification by minimization was done by ER status, chemotherapy type, 
chemotherapy timing and trastuzumab timing according to the protocol. 
Randomization was at any point prior to cycle 10 of trastuzumab. 
 
Cardiac endpoints 
‘Clinical cardiac dysfunction’ was defined as any or all of the following: symptoms or 
signs of CHF or new / altered cardiac medication prescribed during the 12 months 
after starting trastuzumab. Patients on trastuzumab were reviewed by the study team 
on site every 3 weeks, and every 3 months ‘clinical cardiac dysfunction’ was reported 
on the case record forms, to the trials office. Patients were questioned about 
symptoms of CHF and if these were present, examined by a physician for signs of 
CHF. Other cardiac events included cardiac death, defined as death with at least one 
cause recorded relating to a cardiac issue. ‘Low LVEF’ was a cardiac endpoint, and 
was defined as left ventricular ejection fraction (LVEF) measurement < 50% at any 
point, or a report recording systolic function below normal but without LVEF values. 
LVEF was recorded at the start of trastuzumab (baseline) and at 3-monthly intervals 
for 12 months in both randomized arms and regardless of the timing of 
randomization with respect to start of trastuzumab. Echocardiography (ECHO) or 
multi-gated acquisition cardiac scanning (MUGA) were undertaken, preferably using 
the same method throughout for each individual. Although we recognize that these 
two methods may produce results differing in some aspects, ECHO and MUGA were 
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treated equivalently in the data analysis. Cardiac monitoring did not routinely 
continue after 12 months, although some later LVEF measurements were available. 
Treatment modifications 
Patients developing clinical cardiac dysfunction underwent full cardiac assessment. If 
LVEF fell below 50%, the protocol advised ‘holding’ trastuzumab and repeating 
LVEF at 6 week intervals until LVEF returned to ≥ 50%. Only two delays for a 
maximum of 3 months on account of cardiac toxicity were allowed before 
trastuzumab was discontinued permanently. In the case of New York Heart 
Association (NYHA) class III/IV heart failure symptoms (breathlessness at rest or on 
minimal exertion) trastuzumab was permanently discontinued even after resolution of 
symptoms or normalization of LVEF with treatment (Nomenclature and Criteria for 
Diagnosis of Diseases of the Heart and Great Vessels pp. 253–256, 1994; Raphael 
et al, 2007). 
 
Statistical analysis 
Randomized treatment arms and assessment periods were compared by the number 
of patients reporting treatment modification or cardiac endpoints and course 
delivered dose intensity (CDDI) (Earl et al, 2008) of trastuzumab using chi-squared 
tests with continuity corrections. Patients’ baseline LVEF and the relative changes at 
6 and 12 months were assessed using Wilcoxon signed rank tests and Wilcoxon 
rank sum test. 
 
Random effects modelling was applied to patients’ LVEF over time, and results 
presented graphically as the mean patient values over time for each treatment arm 
as predicted by the model. Further random effects modelling investigated the 
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influence of chemotherapy type, trastuzumab timing and number of anthracycline 
cycles. The influence of predictive factors for development of cardiac dysfunction 
(patients with clinical cardiac dysfunction or a low LVEF during the 12-month 
reporting period) were assessed using logistic regression and presented with odds 
ratios and 95% CIs. 
 
Statistical analysis was on an intention-to-treat basis and therefore all patients were 
analyzed within their randomized treatment arms. All reported p-values are two-
sided. Analysis was undertaken by Warwick Clinical Trials Unit, using SAS statistical 
software (version 9.3), following the pre-defined trial Statistical Analysis Plan. 
Persephone is registered with EudraCT (2006-007018-39), ISRCTN (52968807), 
and ClinicalTrials.gov (NCT00712140). 
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RESULTS 
Patients 
The first 2500 patients were randomized into the Persephone trial between October 
2007 and December 2012 (Figure 1); 1251 were randomized to 12-months and 1249 
to 6-months trastuzumab. These subgroups appeared balanced across treatment 
arms in terms of patient characteristics and prognostic variables (Table 1), and were 
representative of the whole Persephone patient sample (values for all 4088 patients 
shown in parenthesis): median age 55 years (56 years); 94% white (93%); 61% post-
menopausal (61%); 67% ER positive (69%); 48% <=2cm diameter (49%); 67% 
grade 3 (66%); and 58% node negative (59%). During follow-up 59/2500 (2.4%) of 
the patients recurred (local or distant) within 12 months of starting trastuzumab. 
 
Chemotherapy, cardiac medication prior to trastuzumab and timing of 
randomization 
93% (2335/2500) of patients received an anthracycline as part of either 
anthracycline-based (48% [1199/2500]) or anthracycline plus taxane-based (45% 
[1136/2500]) chemotherapy. 65% received trastuzumab sequentially to 
chemotherapy and 35% concomitantly with the non-anthracycline component. Full 
chemotherapy details are shown in Tables 1 and 2. Only 2% (50/2500) of patients, 
balanced across randomized treatment arms, reported being on cardiac medication 
prior to start of trastuzumab (Table 1). Randomisation was before the start of 
trastuzumab or at any time before the 10th cycle. 55% (1365/2500) were randomized 
up-front, and 82% (2039/2500) prior to cycle 4 (Supplementary Table 1), balanced 
across randomised treatment arms.  
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Trastuzumab modifications 
Complete trastuzumab treatment data are available on 2433 (97%) of the 2500 
patients (Figure 1). Of those randomized to the12-month arm, 85 (7%) received 1-9 
cycles and 1129 (93%) received >10 cycles of trastuzumab (Figure 1 and Supp 
Figure 1). Of those randomised to the 6-month arm, 1165 (96%) received 1-9 cycles 
and 51 (4%) received >10 cycles of trastuzumab. Three patients received no 
trastuzumab within the trial due to the diagnosis of metastatic disease. Cardiotoxicity 
was the most common reason for stopping treatment early (n=141) (Supp Figure 1), 
followed by patient request (n=76). Cardiotoxicity was also given as the reason for 
more trastuzumab delays in 12-month than 6-month patients (6% vs 4% of patients 
(p=0.01) (Table 3). Significantly more 6-month patients (1066/1164 [92%]) received 
at least 85% course delivered dose intensity (CDDI), compared with 12-month 
patients (963/1142 [84%]) (p<0.0001). 
 
Cardiac events 
Full clinical cardiac data were available on 2430 patients (97%). Clinical cardiac 
dysfunction was more common in 12-month than 6-month patients (140/1214 [12%] 
vs 105/1216 [9%] respectively, p=0.02) (Table 4). No differences were apparent in 
the first 6 months of trastuzumab (8% of 12-month patients, 7% of 6-month patients 
[p=0.19]). However, a significant difference appeared during the 7-12 months period 
(8% vs 5% respectively [p=0.03]).  
 
A total of 12,147 LVEF measurements (71% ECHO, 17% MUGA, 12% unknown) 
were reported in 2498 patients. The use of each modality was balanced across 
randomized treatment arms. MUGAs appear to have a higher rate of abnormal 
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scores (MUGAs 10% abnormal compared to 4% for ECHOs, Table 4). During the 
first 6 months of treatment, 7% of 12-month patients and 8% of 6-month patients 
recorded low LVEFs (p=0.76). During months 7-12, this increased to 8% of 12-month 
patients but fell to 5% of 6-month patients (p=0.004 for difference between treatment 
arms). Similarly, during the first 6 months of treatment, equal proportions of patients 
across randomized treatment arms recorded significant LVEF falls from baseline, 
with a similar proportion observed in the second 6 months for 12-month patients, but 
lower for 6-month patients (Table 4).  
 
Four cardiac deaths were reported. One was assessed as non-cardiac since at the 
time of death from liver metastases, the patient had well controlled NYHA II heart 
failure. In the other 3 patients post-mortem examination demonstrated ischaemic 
heart disease as the cause of death. In 2 of these 3 patients, all LVEF 
measurements during the 12 months of the trial were normal.   
 
Relative change of LVEF at 6 and 12 months  
2420 patients had an LVEF measured at baseline and at least one other time-point; 
1204 12-month and 1216 6-month patients (Supp Table 2). The two treatment arms 
were well matched for baseline LVEF (12-month median 63% [IQR 59-67%], 6-
month median 63% [IQR 60-67%], p=0.22). There were statistically significant 
reductions in LVEF at the 6 and 12 month time-point in both treatment arms (all 
p<0.0001). Although similar relative changes from baseline to 6 months were seen 
across treatment arms (12-month median 0.97 [IQR 0.90-1.02], 6-month median 
0.97 [IQR 0.90-1.02, p=0.38), 12-month patients showed significantly greater 
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reductions in LVEF by 12 months (12-month median 0.96 [IQR 0.89-1.02], 6-month 
median 0.97 [IQR 0.91-1.03, p=0.001). 
 
Landmark cardiac dysfunction analysis from 6 months  
Cardiac data were available from 2081 patients who were free of cardiac events in 
their first 6 months of treatment. Significantly more 12-month patients (66/1046 [6%]) 
than 6-month patients (29/1035 [3%]) were recorded to have a cardiac event in the 
second 6 month period (p=0.0002). 
 
Random effects modelling 
A quadratic curve was found to fit the LVEF data, demonstrating that cardiac function 
recovers post treatment (Figure 2). This was seen for the entire trial population 
(p<0.0001) and for each randomized arm separately (both p<0.0001). There was a 
significant difference between treatments in terms of their change over time (p=0.02); 
quadratic modelling predicts an earlier recovery of cardiac function after treatment 
completion in 6-month patients. No significant differences were found between 
chemotherapy types (p=0.43) or trastuzumab timing (p=0.79) in terms of LVEF 
changes over time (Supp Figure 2A and 2B). 
 
Predictive factors for cardiac dysfunction 
For both 12-month and 6-month patients, lower baseline LVEF increased the odds of 
cardiac dysfunction (reference >65%: 55-<65% OR 1.61 [95%CI 1.26-2.04]<55% OR 
5.22 [95%CI 3.42-7.95])(Table 5). Additionally, increasing age was found to be linked 
to increasing odds of cardiac dysfunction (reference <50: 50-59 OR 1.58 [95%CI 
1.17-2.12], 60-69 OR 1.91 [95%CI 1.42-2.57]) 70+ OR 2.72 [95%CI 1.82-4.08]). 
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Chemotherapy type, left-sided radiotherapy, BMI and ethnicity did not appear to 
influence this endpoint. Receiving >3 cycles of anthracycline was associated with 
increasing odds of developing cardiac dysfunction in the 12-month trastuzumab arm 
(OR 1.41 [95%CI 1.04-1.90]), but not the 6-month arm (OR 1.28 [95%CI 0.91-1.79)]. 
Further random effects modelling showed that >3 compared with <3 cycles of 
anthracycline showed a non-significant trend to lower LVEF and slower recovery in 
the 12-month (p=0.19) but not the 6-month arm (p=0.70) (Supp Figure 3A and 3B). 
In the small number of patients who were taking cardiac medication prior to starting 
trastuzumab (25 in the 12-month arm and 23 in the 6-month arm) both arms were at 
significantly increased risk of developing cardiac dysfunction; 12-month patients had 
higher risk than 6-month patients (OR 12.47 [95%CI 5.14-30.25] v 5.88 [95%CI 2.55-
13.54] respectively). 
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DISCUSSION 
Trastuzumab is a highly effective adjuvant treatment for HER2 positive early breast 
cancer given in addition to chemotherapy. However, cardiotoxicity has been 
demonstrated consistently in patients receiving trastuzumab. In 2500 patients in the 
Persephone trial, we compared cardiotoxicity between the 6- and 12-month arms. 
Significantly more clinical cardiac dysfunction was seen in 12-month patients 
compared with 6-month patients (13% v 10%; p=0.04), and twice as many 12-month 
as 6-month patients stopped early because of cardiac events (8% v 4%: p<0.0001). 
Consequently, fewer 12-month than 6-month patients received course delivered 
dose intensity of >85% (84% vs 92%: p<0.0001). These data are similar to those 
reported from the PHARE trial (Pivot et al, 2015). In addition, the HERA trial (Procter 
et al, 2010) has reported an increased number of patients who developed clinical 
cardiac dysfunction and reduced LVEF measurements in the 24-month trastuzumab 
arm. Since 24 months treatment has not been shown to be more effective than the 
standard of 12 months and caused more cardiotoxicity, 12 months treatment remains 
the standard at present. 
 
Could the risk of cardiac dysfunction from trastuzumab be decreased by reducing the 
length of adjuvant treatment?  In the Persephone trial the principal research question 
concerns the non-inferiority for disease-free survival of 6 months compared with the 
standard of 12 months. In accordance with the trial statistical analysis plan, the 
primary endpoint will be analyzed in late 2017. If 6 months treatment proves to be 
non-inferior to 12 months in terms of disease-free survival, then the reduced cardiac 
problems reported for 6-months trastuzumab will provide an additional reason to 
adopt 6 months in place of the standard 12 months treatment.  
Page 19 of 33 
 
 
 
Our modelling of the LVEF measurements on the whole population shows some 
interesting comparisons between the 6 and 12 month arms. Both appear to fit best 
into a quadratic model during treatment and on recovery. For the 12-month arm, the 
LVEF data show a lower LVEF nadir and a slower recovery than for the 6-month 
arm. This suggests that the longer the trastuzumab treatment, the greater the 
cardiac dysfunction and the longer the recovery time. This effect may not be limited 
to those with LVEF falls to <50% and could potentially result in long term 
susceptibility to adverse cardiac events because of a longer, more marked period of 
myocardial stress. These findings would be another reason to reduce adjuvant 
trastuzumab to 6 months if this length of treatment proves non-inferior to 12 months. 
 
The methods used to measure LVEF highlighted some interesting issues. ECHO 
was more frequently used (71% of cases) than MUGA (17% of cases), however 
MUGAs had 10% abnormal values compared with only 4% for ECHOs. It is possible 
that MUGAs are more sensitive than ECHOs, or alternatively that MUGAs were the 
‘preferred’ modality when cardiac problems were suspected on clinical grounds. 
Moreover in some hospitals the normal range of LVEF measured by MUGA is lower 
(e.g. >43%) than that for ECHO (≥55%), which means that it is more likely that a 
MUGA result will be <50%. In our analysis, following National Guidelines we took a 
cut-off of 50% regardless of modality of assessment and this is likely to have 
influenced the incidence of ‘abnormal’ results, for the MUGA investigations. 
 
Some researchers have reported genetic alterations within the HER2 receptor that 
may predispose to cardiac toxicity from trastuzumab (Beauclair et al, 2007; Ng et al, 
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2014; Halyard et al, 2009). In a companion translational pharmaco-genetic research 
study (Persephone PGSNPs), a blood sample collection is in progress which will 
allow us not only to validate these potential predictive genetic alterations but also in 
a genome-wide association study, to discover other possible genetic predisposition 
factors for trastuzumab-induced cardiotoxicity.  
 
Our study shows that regardless of 6 or 12-month therapy, both age and baseline 
LVEF are important predictive factors for cardiac dysfunction. As a surrogate for 
radiotherapy effects we compared patients who had right with those with left sided 
tumors. Despite other reports of increased cardiotoxicity after radiotherapy for left-
sided HER2 positive breast cancer (Roca et al, 2013), we did not find an interaction 
with radiotherapy and sidedness, although the follow-up is relatively short. In terms 
of age, comparing patients under 50 years, with those in the next two decades, and 
those over 70 years, shows an increasing risk with age. Those over 70 years have 
an odds ratio of 2.63 for cardiac dysfunction, which would suggest that the predicted 
benefit of trastuzumab in this age group would have to be significant to balance the 
risk of cardiac dysfunction. In terms of lower baseline LVEF, patients with LVEF 
between 50 and 55%, have an odds ratio of 5.36 [95% CI 3.53-8.14]) of developing 
cardiac dysfunction with low LVEF measurements when compared to a reference of 
>65%. However, these data should be interpreted cautiously since if a patient is at 
baseline close to the lower limit of normal LVEF value (50%), then even a small 
absolute % LVEF fall, possibly not clinically meaningful, would take them below this 
normal threshold. Anthracyclines have been demonstrated to significantly compound 
trastuzumab cardiotoxicity, nowhere more elegantly that in the BCIRG trial (Slamon 
et al, 2011) which excluded anthracyclines in one experimental arm. In many studies 
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this interactive effect is significantly greater when more than 3 cycles of 
anthracycline are given. Our study is the first to observe a differential effect between 
6 and 12 months of trastuzumab therapy, with more than 3 cycles of anthracycline 
predicting a higher risk of cardiac toxicity in the 12-month but not the 6-month arm 
(OR 1.43 [95% CI 1.06-1.92] and 1.12 [0.81-1.55] respectively). Although Slamon 
and colleagues have shown that anthracyclines can be substituted by carboplatin 
and long term outcomes are not significantly different, nevertheless anthracyclines 
are highly effective chemotherapeutic agents (Poole et al, 2006) and are still 
received by the majority of breast cancer patients in the adjuvant setting. In addition 
CEP17 and topo-isomerase II amplification (more common in the HER2 positive 
population) have been reported in a meta-analysis to be predictive biomarkers of 
anthracycline benefit (Bartlett et al, 2015). Controversy remains with regards to 
discontinuing the use of anthracyclines altogether in HER2 positive disease, and 
therefore we should endeavor to develop guidance to maximise the cardiac safety of 
the anthracycline / trastuzumab combination. 
 
Often clinical trials exclude patients with common risk factors. This can limit the 
general applicability of their results and significant genetic differences have been 
demonstrated between patients in clinical trials and those included in the Cancer 
Genome Atlas (Geifman and Butte, 2016). It is important to emphasise that the 
Persephone trial was designed to ‘map on to standard NHS practice’ in the ‘real 
world’: The patients included in the trial have the same cardiac risk profile as those 
receiving standard chemotherapy followed by 12 months trastuzumab. This has 
important implications for the interpretation and applicability of the results of this 
cardiology sub-study and of the future non-inferiority comparison of efficacy. 
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In conclusion, in the 2500 patient Persephone cardiology sub-study, patients on the 
6-month arm had significantly fewer cardiac events than the 12-month patients, 
particularly if they had received >3 cycles of anthracyclines. 
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Supplementary Figure 2A and 2B: Random Effects Modelling predicted lines, 
split by chemotherapy type and trastuzumab timing 
Supplementary Figure 3A and 3B: Random effects modelling predicted lines, 
split by number of anthracycline doses 
Patients randomly assigned as of 7th December 2012 
n=2500 
12 months of Trastuzumab 
One initial dose, 8mg/kg IV 
17 maintenance doses, 6mg/kg IV every 3 weeks 
(n=1251) 
6 months of Trastuzumab 
One initial dose, 8mg/kg IV 
8 maintenance doses, 6mg/kg IV every 3 weeks 
(n=1249) 
1215/1251 (97%) with full treatment data available 
 
Trastuzumab doses received prior to relapse 
   None (n=1 (<1%)) 
   Between 1 and 9 doses (n=85 (7%)) 
   10 or more doses (n=1129 (93%)) 
1218/1249 (98%) with full treatment data available 
 
Trastuzumab doses received prior to relapse 
   None (n=2 (<1%)) 
   Between 1 and 9 doses (n=1165 (96%)) 
   10 or more doses (n=51 (4%)) 
Cardiac endpoints 
3 Cardiac deaths (0.2% of 1251) 
140 patients with clinical cardiac dysfunction (12% of 1214 with full 
data available on their treatment doses) 
146 patients with low LVEFs (12% of 1249 with LVEF results reported) 
Cardiac endpoints 
1 Cardiac death (0.08% of 1249) 
105 patients with clinical cardiac dysfunction (9% of 1216 with full 
data available on their treatment doses) 
117 patients with low LVEFs (9% of 1249 with LVEF results reported) 
Figure 1: Flow chart of cardiac follow-up and events 
12 months 
pts 6 months pts Total
N (%) N (%) N (%)
Median (range) 55 (22-79) 55 (23-82) 55 (22-82)
<35 years old 30 (2) 30 (2) 60 (2)
35 – 49 years old 372 (30) 358 (29) 730 (29)
50 – 59 years old 400 (32) 425 (34) 825 (33)
60 -70 years old 363 (29) 336 (27) 699 (28)
70 + years old 86 (7) 100 (8) 186 (8)
White 1021 (93) 1019 (95) 2040 (94)
Asian 31 (3) 23 (2) 54 (2)
Black 36 (3) 23 (2) 59 (3)
Other 12 (1) 11 (1) 23 (1)
High 838 (68) 851 (69) 1689 (68)
Normal 387 (31) 369 (30) 756 (31)
Low 12 (1) 14 (1) 26 (1)
Pre 366 (33) 345 (32) 711 (32)
Peri 75 (7) 80 (7) 155 (7)
Post 670 (60) 658 (61) 1328 (61)
Negative 418 (33) 416 (33) 834 (33)
Positive 833 (67) 833 (67) 1666 (67)
<=2cm 560 (48) 560 (48) 1120 (48)
>2 and <=5cm 529 (46) 540 (47) 1069 (46)
>5cm 67 (6) 63 (5) 130 (6)
I (well diff.) 18 (2) 22 (2) 40 (2)
II (mod. diff.) 352 (30) 360 (31) 712 (31)
III (poor diff.) 783 (68) 777 (67) 1560 (67)
Negative 707 (57) 719 (58) 1426 (58)
1–3 nodes positive 348 (28) 354 (29) 702 (28)
4+ nodes positive 191 (15) 164 (13) 355 (14)
Anthracycline based 600 (48) 599 (48) 1199 (48)
Taxane based 81 (7) 80 (6) 161 (6)
Anthracycline + Taxane based 568 (45) 568 (46) 1136 (46)
No taxane and no anthracycline 2 (<1) 2 (<1) 4 (<1)
Adjuvant 1093 (87) 1092 (87) 2185 (87)
Neo-adjuvant 158 (13) 157 (13) 315 (13)
Concurrent 442 (35) 441 (35) 883 (35)
Sequential 809 (65) 808 (65) 1617 (65)
Yes 26 (2) 24 (2) 50 (2)
No 1225 (98) 1225 (98) 2450 (98)
Reported prior use of cardiac medication
TREATMENT DETAILS
Chemotherapy type
Chemotherapy timing
Trastuzumab timing
Nodal Status at surgery [2483 (99%) known)]
BMI [2471 (99%) known)]
Table 1: Patient, Tumor and Treatment details of the first 2500 Persephone patients
PATIENT DETAILS
Age at diagnosis
Ethnicity [2176 (87%) known)]
Menopausal status prior to chemotherapy [2194 (88%) known)]
TUMOUR DETAILS
ER status
Tumor size of largest invasive tumor at surgery [2319 (93%) known)]
Tumor Grade [2410 (96%) known)]
Anthracycline 
based Taxane based
Anthracycline + 
Taxane based
No taxane, no 
anthracycline
N (%) N (%) N (%) N (%)
Adjuvant 1163 (53) 159 (7) 859 (39) 4 (1)
Neo-adjuvant 36 (11) 2 (1) 277 (88) 0 (0)
Concurrent 50 (6) 115 (13) 718 (81) 0 (0)
Sequential 1149 (71) 46 (3) 418 (25) 4 (1)
Chemotherapy timing
Trastuzumab timing
Table 2: Chemotherapy type across Chemotherapy and Trastuzumab timing
12 months pts 6 months pts p
Number of patients 1214 1216
   Treatment data in the 1st 6-month period 1214 1216
   Treatment data in the 2nd 6-month period 1129 51*
No. of Patients reporting delays 717 (59%) 496 (41%) <0.0001
   In 1st 6-month period 520/1214 (43%) 487/1216 (40%)
   In 2nd 6-month period 424/1129 (38%) 20/51 (39%)
No. of Patients reporting delays due to cardiotoxicity 72 (6%) 45 (4%) 0.01
   In 1st 6-month period 40/1214 (3%) 43/1216 (4%)
   In 2nd 6-month period 33/1129 (3%) 2/51* (4%)
* Doses administered to patients who continued trastuzumab treatment beyond their randomized 6 months 
(9 doses).
Table 3: Trastuzumab treatment modifications by the 2430 patients with complete trastuzumab 
treatment information and who received trastuzumab
Overall In 1
st 6 
months
In 2nd 6 
months
Overall In 1
st 6 
months
In 2nd 6 
months
Clinical cardiac dysfunction #
140/1214 
(12%)
102/1214 
(8%)
91/1196 
(8%)
105/1216 
(9%)
84/1216 
(7%)
62/1174 
(5%)
   Symptoms of CHF ‡ 78 55 41 53 41 22
   Signs of CHF 27 21 12 17 15 7
   New medication for cardiac disease 97 65 72 75 62 52
Low LVEF *
146/1249 
(12%)
91/1249 
(7%)
101/1201 
(8%)
117/1249 
(9%)
96/1249 
(8%)
59/1114 
(5%)
Cardiac death † 3/1251 0/1251 0/1234^ 1/1249 0/1249 0/1230^
An absolute decrease from baseline of 
>=10% to below 50%
106/1204 
(9%)
63/1198 
(5%)
68/1162 
(6%)
89/1216 
(7%)
68/1214 
(6%)
43/1086 
(4%)
An LVEF<50% after a baseline of 
>=59%
68/1204 
(6%)
37/1198 
(3%)
47/1162 
(4%)
57/1216 
(5%)
46/1214 
(4%)
23/1086 
(2%)
Incidence of low LVEF tests ∞
305/6342 
(5%)
146/3850 
(4%)
159/2492 
(6%)
242/5805 
(4%)
155/3790 
(4%)
87/2015 
(4%)
   MUGA 
117/1104 
(11%)
61/641 
(10%)
56/463 
(12%)
96/959 
(10%)
67/606 
(11%)
29/353 
(8%)
   ECHO 
185/4479 
(4%)
84/2475 
(3%)
101/2004 
(5%)
142/4119 
(3%)
85/2474 
(3%)
57/1645 
(3%)
   Unknown 
3/759 
(<1%)
1/734 
(<1%)
2/25 
(8%)
4/727 
(<1%)
3/710 
(<1%)
1/17 
(6%)
  ‡ CHF = congesƟve heart failure
∞ Incidence of low LVEF tests out of the total number of tests in the Ɵme period
^ Denominators reduced from entire patient set due to either deaths due to non-cardiac reasons or 
withdrawal of consent for further follow-up within the first 6 month period.
Table 4: Cardiac endpoints
12 months pts 6 months pts
Number of patients reporting at least one incidence of … ¥
PERSEPHONE defined cardiac endpoints
Significant LVEF falls
¥ Patients could experience a cardiac endpoint in both of the 6 month intervals.
Number of LVEF tests reported as low
# Clinical cardiac dysfunction = Symptoms of cardiac disease, or Signs of congestive heart failure or new 
medication for cardiac disease
* Low LVEF =  LVEF<50%, or % unknown but classified on report as abnormal 
† 4 deaths have been reported with a ‘cardiac’ cause (3 in 12-month paƟents, 1 in 6-month paƟents). None 
occurred during the first 12 months after starting trastuzumab treatment. 3 patients reported with a cardiac 
cause contributing to  death (2 of the patients on the 12 month arm, and the patient on the 6 month arm) also 
had widespread metastatic disease at the time of death. It is likely that only one death is potentially 
attributable to cardiac complications of treatment (12 month arm). 
Figure 2: Random Effects modelling predicted lines and 95%CIs, split by randomized treatment arm 
Cases 
(n=221)
Controls 
(n=992)
Odds ratios     
(95% CI)
Cases 
(n=172)
Controls 
(n=1044)
Odds ratios  
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(n=393)
Controls 
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Odds ratios     
(95% CI)
Taxane based 13 (16%) 67 (84%) - 10 (13%) 67 (87%) - 23 (15%) 134 (85%) -
Taxane & anthracycline 95 (17%) 457 (83%) 1.07 (0.57-2.02) 68 (12%) 486 (88%) 0.94 (0.46-1.91) 163 (15%) 943 (85%) 1.01 (0.63-1.62)
Anthracycline based (no taxanes) 113 (20%) 466 (80%) 1.25 (0.67-2.34) 93 (16%) 490 (84%) 1.27 (0.63-2.56) 206 (18%) 956 (82%) 1.26 (0.79-2.00)
<=3 cycles 81 (15%) 442 (85%) - 60 (12%) 423 (88%) - 141 (14%) 865 (86%) -
>3 cycles 138 (20%) 536 (80%) 1.41 (1.04-1.90) 109 (15%) 602 (85%) 1.28 (0.91-1.79) 247 (18%) 1138 (82%) 1.33 (1.06-1.67)
>65% 68 (14%) 419 (86%) - 52 (10%) 479 (90%) - 120 (12%) 898 (88%) -
55-<65% 122 (19%) 522 (81%) 1.44 (1.04-1.99) 99 (16%) 508 (84%) 1.80 (1.26-2.57) 221 (18%) 1030 (82%) 1.61 (1.26-2.04)
<55% 26 (51%) 25 (49%) 6.41 (3.50-11.75) 20 (33%) 41 (67%) 4.49 (2.45-8.24) 46 (41%) 66 (59%) 5.22 (3.42-7.95)
No 140 (20%) 568 (80%) - 92 (14%) 581 (86%) - 232 (17%) 1149 (83%) -
Yes 80 (16%) 410 (84%) 0.79 (0.59-1.07) 77 (15%) 449 (85%) 1.08 (0.78-1.50) 157 (15%) 859 (85%) 0.91 (0.73-1.13)
Low/Normal 63 (16%) 323 (84%) - 49 (13%) 322 (87%) - 112 (15%) 645 (85%) -
High 154 (19%) 660 (81%) 1.20 (0.87-1.65) 122 (15%) 709 (85%) 1.13 (0.79-1.62) 276 (17%) 1369 (83%) 1.16 (0.91-1.47)
<50 years old 50 (13%) 337 (87%) - 34 (9%) 339 (91%) - 84 (11%) 676 (89%) -
50-59 years old 71 (18%) 316 (82%) 1.51 (1.02-2.24) 60 (15%) 353 (85%) 1.70 (1.09-2.65) 131 (16%) 669 (84%) 1.58 (1.17-2.12)
60-69 years old 78 (22%) 278 (78%) 1.89 (1.28-2.79) 54 (16%) 277 (84%) 1.94 (1.23-3.07) 132 (19%) 555 (81%) 1.91 (1.42-2.57)
70+ years old 22 (27%) 61 (73%) 2.43 (1.37-4.30) 24 (24%) 75 (76%) 3.19 (1.79-5.70) 46 (25%) 136 (75%) 2.72 (1.82-4.08)
White 184 (18%) 815 (82%) - 142 (14%) 851 (86%) - 326 (16%) 1666 (84%) -
Other 11 (15%) 63 (85%) 0.77 (0.40-1.50) 6 (11%) 49 (89%) 0.73 (0.31-1.75) 17 (13%) 112 (87%) 0.78 (0.46-1.31)
No 203 (17%) 985 (83%) - 161 (14%) 1032 (87%) - 364 (15%) 2017 (85%) -
Yes 18 (72%) 7 (28%) 12.47 (5.14-30.25) 11 (48%) 12 (52%) 5.88 (2.55-13.54) 29 (60%) 19 (40%) 8.46 (4.69-15.25)
Cases = Patients reporting one or more episodes of clinical cardiac dysfunction and/or Low LVEF in the 12 month reporting period.
Controls = Patients reporting no clinical cardiac dysfunction and no Low LVEF in the 12 month reporting period.
Results in bold indicate significant results (i.e. The 95% CI not spanning 1)
Reported prior use of cardiac medication
Left-sided radiotherapy 
BMI
Age at diagnosis 
Ethnicity  
Baseline LVEF 
Anthracyclines
Table 5: Predictive factors for development of cardiac dysfunction, by randomized treatment arm
12 months pts 6 months pts Overall
Chemotherapy 
